Kala Bio (KALA) Non-Current Debt (2016 - 2025)
Kala Bio (KALA) posted Non-Current Debt of $18.8 million for Q2 2025, up 24.24% sequentially from $15.1 million in Q1 2025, and down 17.72% YoY from $22.8 million in Q2 2024.
Kala Bio (KALA) Non-Current Debt (2016 - 2025) Analysis & Trends
Kala Bio has reported Non-Current Debt for 10 years, with the latest figure at $18.8 million in Q2 2025.
- Quarterly Non-Current Debt fell 17.72% year-over-year to $18.8 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $18.8 million (down 17.72% YoY) and the FY2024 annual result came in at $20.1 million, down 41.21% from the prior year.
- Non-Current Debt grew to $18.8 million in Q2 2025 per KALA's latest filing, from $15.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $79.8 million in Q2 2022 and troughed at $15.1 million in Q1 2025.
- A 5-year average of $44.7 million and a median of $34.0 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt increased 9.43% in 2022, then sank 58.08% in 2023.
- Over 5 years, Non-Current Debt stood at $78.9 million in 2021, then tumbled by 51.94% to $37.9 million in 2022, then dropped by 9.88% to $34.2 million in 2023, then plunged by 41.21% to $20.1 million in 2024, then dropped by 6.55% to $18.8 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $18.8 million, $15.1 million, and $20.1 million for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 18.79 Mn |
| Mar 31, 2025 | 15.12 Mn |
| Dec 31, 2024 | 20.10 Mn |
| Sep 30, 2024 | 17.16 Mn |
| Jun 30, 2024 | 22.83 Mn |
| Mar 31, 2024 | 28.51 Mn |
| Dec 31, 2023 | 34.19 Mn |
| Sep 30, 2023 | 33.88 Mn |
| Jun 30, 2023 | 33.57 Mn |
| Mar 31, 2023 | 33.27 Mn |
| Dec 31, 2022 | 37.94 Mn |
| Sep 30, 2022 | 42.64 Mn |
| Jun 30, 2022 | 79.80 Mn |
| Mar 31, 2022 | 79.36 Mn |
| Dec 31, 2021 | 78.93 Mn |
| Sep 30, 2021 | 78.49 Mn |
| Jun 30, 2021 | 78.06 Mn |
| Mar 31, 2021 | 72.52 Mn |
| Dec 31, 2020 | 72.24 Mn |
| Sep 30, 2020 | 71.97 Mn |